{"data":{"type":"company_profile_ai","id":192805,"entity_id":"wefunder:company:192805","attributes":{"canonical_url":"https://wefunder.com/kahf.biotech.inc","retrieval_urls":{"canonical":"https://wefunder.com/kahf.biotech.inc","json":"https://wefunder.com/kahf.biotech.inc.json","markdown":"https://wefunder.com/kahf.biotech.inc.md","ai_json":"https://wefunder.com/kahf.biotech.inc.ai.json","ai_text":"https://wefunder.com/kahf.biotech.inc.ai.txt","changelog_json":"https://wefunder.com/kahf.biotech.inc.changelog.json","schema":"https://wefunder.com/.well-known/ai-profile-schema.json"},"updated_at":"2026-06-04T23:54:18Z","generated_at":"2026-06-05T18:19:50Z","profile_visibility":{"owner_published":true,"public_search_results":true,"site_search_listed":true,"privacy_mode":"promote","invite_only":false},"company":{"id":192805,"entity_id":"wefunder:company:192805","slug":"kahf.biotech.inc","name":"KAHF Biotech, Inc.","tagline":"Building a target-centric therapeutic ecosystem for next-generation cancer treatment","location":"Rochester, NY","website":"https://kahfbiotech.com","total_amount_raised":62000,"total_investors":10,"is_funded":false,"is_active":true},"key_claims":[{"claim_id":"claim-total-raised","text":"Total raised on Wefunder: 62000","citation":"https://wefunder.com/kahf.biotech.inc#claim-total-raised","provenance":{"source":"FrontCompanySummary#amount_raised","last_verified_at":"2026-06-04T23:54:18Z","as_of":"2026-06-05T18:19:50Z","confidence":"high"},"observed_at":"2026-06-04T23:54:18Z","expires_at":"2026-06-05T23:54:18Z"},{"claim_id":"claim-total-investors","text":"Total investors: 10","citation":"https://wefunder.com/kahf.biotech.inc#claim-total-investors","provenance":{"source":"FrontCompanySummary#number_of_investors","last_verified_at":"2026-06-04T23:54:18Z","as_of":"2026-06-05T18:19:50Z","confidence":"high"},"observed_at":"2026-06-04T23:54:18Z","expires_at":"2026-06-05T23:54:18Z"}],"verified_facts":[{"claim_id":"claim-total-raised","text":"Total raised on Wefunder: 62000","citation":"https://wefunder.com/kahf.biotech.inc#claim-total-raised","provenance":{"source":"FrontCompanySummary#amount_raised","last_verified_at":"2026-06-04T23:54:18Z","as_of":"2026-06-05T18:19:50Z","confidence":"high"},"observed_at":"2026-06-04T23:54:18Z","expires_at":"2026-06-05T23:54:18Z"},{"claim_id":"claim-total-investors","text":"Total investors: 10","citation":"https://wefunder.com/kahf.biotech.inc#claim-total-investors","provenance":{"source":"FrontCompanySummary#number_of_investors","last_verified_at":"2026-06-04T23:54:18Z","as_of":"2026-06-05T18:19:50Z","confidence":"high"},"observed_at":"2026-06-04T23:54:18Z","expires_at":"2026-06-05T23:54:18Z"}],"company_claims":{"tagline":"Building a target-centric therapeutic ecosystem for next-generation cancer treatment","story":"Pleased to share that KAHF Biotech, Inc. has announced the filing of patent-pending technology supporting its next-generation therapeutic platform focused on the development of novel cancer therapeutics and diagnostics. The company’s platform-based intellectual property portfolio encompasses a broad range of therapeutic and diagnostic modalities designed to target critical drivers of tumor progression, metastatic disease, and treatment resistance across solid and hematological tumors.The portfolio includes first-in-class approaches spanning antibody-drug conjugates (ADCs), T cell engager, Monoclonal Antibody, CAR-T cell therapies, antibody-oligonucleotide conjugates (AOCs), degrader-antibody conjugates (DACs), DsiRNA-based therapeutics, targeted biologics, companion diagnostics, and additional precision oncology applications. The platform is designed to support the development of multiple therapeutic strategies across diverse cancer indications while enabling future expansion into combination therapies and translational diagnostic technologies.This patent-pending platform represents an important milestone in KAHF Biotech’s mission to advance innovative therapeutic approaches for patients with aggressive cancers. We believe the breadth of this platform provides significant opportunities for future therapeutic development, strategic partnerships, and translational research.KAHF Biotech continues to advance preclinical research and platform development efforts focused on translating emerging scientific discoveries into targeted oncology therapeutics.“Our vision is to revolutionize cancer treatment particularly metastatic disease by developing impactful, effective, and affordable therapies that are accessible to cancer patients worldwide. We aim to overcome the current challenges of metastatic disease and ensure that groundbreaking treatments reach those who need them most, no matter where they are.”Muhammad Sadeqi Nezhad, Ph.D.Founder \u0026amp; Chief Executive OfficerKAHF Biotech, Inc.","quick_facts":["A novel target in PDAC with limited prior characterization and promising preclinical validation","Dual therapeutic strategy: blocks metastasis early and kills tumors in late-stage disease","Capital-efficient plan: lead antibody development achievable at low cost","Platform approach expandable to multiple solid tumors expressing the same receptor","Lead antibody can be expanded into ADC, CAR-T cells, and Degrader Antibody conjugates (DACs)","Founded by PhD cancer scientist with deep expertise in cancer therapeutic development platforms"]},"computed_metrics":{"total_amount_raised":62000,"total_investors":10,"team_size":1,"featured_investor_count":1,"faq_count":0,"recent_post_count":0},"quick_facts":[{"claim_id":"claim-fact-1","value":"A novel target in PDAC with limited prior characterization and promising preclinical validation","citation":"https://wefunder.com/kahf.biotech.inc#claim-fact-1","observed_at":"2026-06-04T23:54:18Z","expires_at":"2026-06-11T23:54:18Z"},{"claim_id":"claim-fact-2","value":"Dual therapeutic strategy: blocks metastasis early and kills tumors in late-stage disease","citation":"https://wefunder.com/kahf.biotech.inc#claim-fact-2","observed_at":"2026-06-04T23:54:18Z","expires_at":"2026-06-11T23:54:18Z"},{"claim_id":"claim-fact-3","value":"Capital-efficient plan: lead antibody development achievable at low cost","citation":"https://wefunder.com/kahf.biotech.inc#claim-fact-3","observed_at":"2026-06-04T23:54:18Z","expires_at":"2026-06-11T23:54:18Z"},{"claim_id":"claim-fact-4","value":"Platform approach expandable to multiple solid tumors expressing the same receptor","citation":"https://wefunder.com/kahf.biotech.inc#claim-fact-4","observed_at":"2026-06-04T23:54:18Z","expires_at":"2026-06-11T23:54:18Z"},{"claim_id":"claim-fact-5","value":"Lead antibody can be expanded into ADC, CAR-T cells, and Degrader Antibody conjugates (DACs)","citation":"https://wefunder.com/kahf.biotech.inc#claim-fact-5","observed_at":"2026-06-04T23:54:18Z","expires_at":"2026-06-11T23:54:18Z"},{"claim_id":"claim-fact-6","value":"Founded by PhD cancer scientist with deep expertise in cancer therapeutic development platforms","citation":"https://wefunder.com/kahf.biotech.inc#claim-fact-6","observed_at":"2026-06-04T23:54:18Z","expires_at":"2026-06-11T23:54:18Z"}],"latest_fundraise":{"id":156346,"entity_id":"wefunder:fundraise:156346","state":"successful","offering_type":"4(a)(6)","structure":"ttw","testing_the_waters":true,"can_invest_now":false,"funding_started_at":null,"funding_closed_at":null},"investor_memos":[],"team":[{"id":6538073,"entity_id":"wefunder:company_role:6538073","name":"Muhammad Sadeqi Nezhad","title":"CEO","role":"founder","profile_url":"https://wefunder.com/muhammad.sadeqi.nezhad"}],"featured_investors":[{"id":12992,"entity_id":"wefunder:company_investor_profile:12992","name":"Ronald L Krall","bio":"Former Chief Medical Officer, GlaxoSmithKline; Head US Development, AstraZeneca Chairman of the Board, Pierian Biosciences Senior Advisor, EIT Pharma","profile_url":"https://wefunder.com/ronald.l.krall","endorsement_quote":"As a former executive (Chief Medical Officer \u0026amp; Head of Development) with responsibility for medicines development for Zeneca, AstraZeneca and GSK I oversaw the development of more than 20 medicines, including multiple anti-cancer drugs. The research that underpins KAHF's approach to cancer chemotherapy is novel and warrants development investment. An investment to carry this foundational work forwards to try to make a new anti-cancer agent is potentially transformative. The initial target of this development, pancreatic cancer, is undoubtedly one of the cancers most in need of novel therapeutics. KAHF has a path to making a new medicine that is sound and achievable and accounts for the high risk associated with any new drug development. I back KAHF to fulfill the hope of changing the course of cancer."}],"relationships":[{"source_entity_id":"wefunder:company:192805","relation":"has_team_member","target_entity_id":"wefunder:user:4966172","target_url":"https://wefunder.com/muhammad.sadeqi.nezhad"},{"source_entity_id":"wefunder:company:192805","relation":"has_featured_investor","target_entity_id":"wefunder:user:4985457","target_url":"https://wefunder.com/ronald.l.krall"},{"source_entity_id":"wefunder:company:192805","relation":"has_latest_fundraise","target_entity_id":"wefunder:fundraise:156346"}],"faq":[],"recent_posts":[],"provenance":{"source":"wefunder_public_company_profile","as_of":"2026-06-05T18:19:50Z","claims":{"total_amount_raised":{"source":"FrontCompanySummary#amount_raised","last_verified_at":"2026-06-04T23:54:18Z","as_of":"2026-06-05T18:19:50Z","confidence":"high"},"total_investors":{"source":"FrontCompanySummary#number_of_investors","last_verified_at":"2026-06-04T23:54:18Z","as_of":"2026-06-05T18:19:50Z","confidence":"high"},"active_raise_states":{"source":"Fundraise.visible(nil, nil)","last_verified_at":"2026-02-24T01:26:47Z","as_of":"2026-06-05T18:19:50Z","confidence":"high"},"latest_fundraise_state":{"source":"Fundraise.visible(nil, nil).order(funding_started_at)","last_verified_at":"2026-02-24T01:26:47Z","as_of":"2026-06-05T18:19:50Z","confidence":"medium"}}}}}}